Drug Type Small molecule drug |
Synonyms STM 9005, STM9005 |
Target |
Action inhibitors |
Mechanism METTL1 inhibitors(methyltransferase 1, tRNA methylguanosine inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Myeloid Leukemia | Preclinical | United Kingdom | 28 Apr 2025 | |
| Acute Myeloid Leukemia | Preclinical | United Kingdom | 28 Apr 2025 | |
| Advanced cancer | Preclinical | United Kingdom | 28 Apr 2025 | |
| Advanced cancer | Preclinical | United Kingdom | 28 Apr 2025 | |
| Melanoma | Preclinical | United Kingdom | 28 Apr 2025 | |
| Melanoma | Preclinical | United Kingdom | 28 Apr 2025 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | United Kingdom | 28 Apr 2025 | |
| Pancreatic Ductal Adenocarcinoma | Preclinical | United Kingdom | 28 Apr 2025 | |
| Neoplasms | Preclinical | New Zealand | 05 Apr 2024 |





